Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Gilles Salles, Stephen J. Schuster, Sven De Vos, Nina D. Wagner-Johnston, Andreas Viardot, Kristie A. Blum, Christopher R. Flowers, Wojciech J. Jurczak, Ian W. Flinn, Brad S. Kahl, Peter Martin, Yeonhee Kim, Sanatan Shreay, Matthias Will, Bess Sorensen, Madlaina Breuleux, Pier Luigi Zinzani, Ajay K. Gopal

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e156-e159
JournalHaematologica
Volume102
Issue number4
DOIs
StatePublished - Mar 31 2017

ASJC Scopus subject areas

  • Hematology

Cite this

Salles, G., Schuster, S. J., De Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., Flowers, C. R., Jurczak, W. J., Flinn, I. W., Kahl, B. S., Martin, P., Kim, Y., Shreay, S., Will, M., Sorensen, B., Breuleux, M., Zinzani, P. L., & Gopal, A. K. (2017). Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica, 102(4), e156-e159. https://doi.org/10.3324/haematol.2016.151738